- Home
- VRAX vs SONN Comparison
VRAX vs SONN Comparison
Compare VRAX & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- SONN
- Stock Information
- Founded
- VRAX 2013
- SONN N/A
- Country
- VRAX United Kingdom
- SONN United States
- Employees
- VRAX N/A
- SONN N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- SONN Health Care
- Exchange
- VRAX Nasdaq
- SONN Nasdaq
- Market Cap
- VRAX 4.7M
- SONN 3.8M
- IPO Year
- VRAX 2022
- SONN N/A
- Fundamental
- Price
- VRAX $0.98
- SONN $1.25
- Analyst Decision
- VRAX Strong Buy
- SONN Strong Buy
- Analyst Count
- VRAX 1
- SONN 1
- Target Price
- VRAX $3.00
- SONN $20.00
- AVG Volume (30 Days)
- VRAX 64.0K
- SONN 39.8K
- Earning Date
- VRAX 02-05-2025
- SONN 05-13-2025
- Dividend Yield
- VRAX N/A
- SONN N/A
- EPS Growth
- VRAX N/A
- SONN N/A
- EPS
- VRAX N/A
- SONN N/A
- Revenue
- VRAX $84,872.00
- SONN $1,000,000.00
- Revenue This Year
- VRAX $5,169.18
- SONN $5,376.22
- Revenue Next Year
- VRAX $66.97
- SONN N/A
- P/E Ratio
- VRAX N/A
- SONN N/A
- Revenue Growth
- VRAX 7.03
- SONN 978.39
- 52 Week Low
- VRAX $0.82
- SONN $1.08
- 52 Week High
- VRAX $9.00
- SONN $16.00
- Technical
- Relative Strength Index (RSI)
- VRAX 44.60
- SONN 51.70
- Support Level
- VRAX $0.91
- SONN $1.13
- Resistance Level
- VRAX $1.03
- SONN $1.21
- Average True Range (ATR)
- VRAX 0.08
- SONN 0.08
- MACD
- VRAX -0.00
- SONN 0.00
- Stochastic Oscillator
- VRAX 24.46
- SONN 56.67
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.